High-risk low-grade gliomas are currently treated with temozolomide and radiotherapy; for these patients, MGMT promoter methylation represents an independent prognostic factor: particularly, unmethylated MGMT promoter is associated with worse prognosis [116]. The gene discussed is MGMT; the disease is central nervous system cancer.